

CLAIMS:

1. Use of a conjugate of the general formula
L-X
- 5 where the group L comprises a ligand capable of binding to activated macrophages and the group X comprises an immunogen, a cytotoxin, or another compound capable of altering macrophage function, in the manufacture of a medicament for treating lupus erythematosus.
2. The use of claim 1 wherein the group L comprises a vitamin, or
10 a vitamin-receptor binding analog or derivative thereof.
3. The use of claim 1 or 2 wherein L comprises a folate receptor binding ligand.
4. The use of claim 1 wherein L comprises an antibody or an activated macrophage binding antibody fragment.
- 15 5. The use of claim 1, 2, or 3 wherein the group X comprises an immunogen.
6. The use of claim 1, 2, or 3 wherein the group X comprises a cytotoxin.
7. The use of claim 6 wherein the group X further comprises a
20 liposome.
8. The use of claim 2 wherein the group X comprises a cytokine.